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Abstract
Antigen B (EgAgB) is the most abundant and immunogenic antigen produced by the larval stage (metacestode) of
Echinococcus granulosus. It is a lipoprotein, the structure and function of which have not been completely elucidated. EgAgB
apolipoprotein components have been well characterised; they share homology with a group of hydrophobic ligand
binding proteins (HLBPs) present exclusively in cestode organisms, and consist of different isoforms of 8-kDa proteins
encoded by a polymorphic multigene family comprising five subfamilies (EgAgB1 to EgAgB5). In vitro studies have shown
that EgAgB apolipoproteins are capable of binding fatty acids. However, the identity of the native lipid components of
EgAgB remains unknown. The present work was aimed at characterising the lipid ligands bound to EgAgB in vivo. EgAgB
was purified to homogeneity from hydatid cyst fluid and its lipid fraction was extracted using chloroform:methanol
mixtures. This fraction constituted approximately 40–50% of EgAgB total mass. High-performance thin layer
chromatography revealed that the native lipid moiety of EgAgB consists of a variety of neutral (mainly triacylglycerides,
sterols and sterol esters) and polar (mainly phosphatidylcholine) lipids. Gas-liquid chromatography analysis showed that
16:0, 18:0 and 18:1(n-9) are the most abundant fatty acids in EgAgB. Furthermore, size exclusion chromatography coupled
to light scattering demonstrated that EgAgB comprises a population of particles heterogeneous in size, with an average
molecular mass of 229 kDa. Our results provide the first direct evidence of the nature of the hydrophobic ligands bound to
EgAgB in vivo and indicate that the structure and composition of EgAgB lipoprotein particles are more complex than
previously thought, resembling high density plasma lipoproteins. Results are discussed considering what is known on lipid
metabolism in cestodes, and taken into account the Echinococcus spp. genomic information regarding both lipid
metabolism and the EgAgB gene family.
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Introduction
The larval stage of the cestode parasite Echinococcus granulosus is
the causative agent of cystic echinococcosis (hydatid disease) in a
range of mammalian species (mainly domestic ungulates) as well as
in humans. It is a unilocular fluid-filled cyst, which steadily grows
inside host visceras (mostly liver and lung). One of the major
molecules produced in large amounts by the cyst is a highly
immunogenic lipoprotein named antigen B (EgAgB) [1,2], which
represents a major diagnostic antigen for human infection [3–5].
This antigen is present in various larval locations including the
parasite cellular layer of the cyst wall (germinal layer), the larval
worms or protoscolex (asexually produced towards inside the cyst)
and the hydatid cyst fluid (HCF). HCF is a complex mixture of
parasite excretory-secretory products and host-derived molecules
that constitutes the liquid content of the cyst [6–8]. Evidence for
EgAgB presence in host circulation is very limited [9]. The strong
antibody response mounted by infected patients against this
antigen indicates that it is likely released into the host-parasite
interface. However, it is unknown whether it is released
throughout the infection or just at a certain time point [10,11].
A lot of efforts have been made to understand the molecular
composition/organization of EgAgB (reviewed by [12]). The native
antigen is a lipoprotein which exhibits an estimated molecular
weight of 120 to 160 kDa according to sedimentation equilibrium
and gel filtration studies, respectively [1,2]. The apolipoprotein
components of EgAgB are encoded by a polymorphic multigene
family that comprises five clades named EgAgB1 to EgAgB5 [13–17].
There is a longand yetunsettled controversy regardingEgAgB gene
copy number. Based on the characterisation of E. granulosus isolates
from different geographic origins, a recent study has proposed that
there are at least 10 EgAgB distinct genes, including four and three
different genes corresponding to the EgAgB3 and EgAgB4 clades
[18]. However, a recent analysis of EgAgB loci in the current
assembly of E. granulosus genome revealed the presence of seven
EgAgB loci clustered on a discrete region of the genome, with one
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slightly differing copies of EgAgB3 [19]. Outside this cluster only an
EgAgB pseudogene was detected. However, the authorsdid not rule
out the possibility of additional EgAgB genes in extra-chromosomal
DNA arrays that might have slipped the genome assembly process
[19]. There is evidence that EgAgB genes are differentially
expressed in single life-cycle parasite stages, and also within distinct
tissues of a same parasite stage (i.e. protoscolex and germinal layer)
[18], suggesting that structural and/or functional differences
between individual EgAgB lipoproteins may exist. The comparison
of the amino acid sequences between members of EgAgB family
showed that members of the EgAgB1, EgAgB3 and EgAgB5 clades
are more similar among each other than to members of the EgAgB2
and EgAgB4 clades and vice versa [18]. The polypeptides encoded
by these genes are between 65 and 71 amino acids long, and have
approximately 8 kDa in mass; reason by which these apolipopro-
teins have traditionally been called EgAgB8/1 to EgAgB8/5. Some
of them were found to be capable of self-associating into homo- or
hetero-oligomers of 16 and 24 kDa [20] or even into higher order
homo-oligomers [21].
Although EgAgB has been studied in some detail at the protein
level, very little is known concerning its lipid moiety. EgAgB was
originally described as a lipoprotein on the basis that lipids were
non-covalently bound to the protein component since they could
be mostly removed by extraction with alcohol/ether mixtures [2].
However, the characterisation of the lipid component has not been
attempted; neither has the protein/lipid stoichiometry been
determined nor the class lipid composition. More recently, it has
been shown that EgAgB apolipoproteins belongs to a family of
hydrophobic ligand binding proteins, referred to as HLBPs, found
exclusively in cestode organisms. To date, members of this family
include intracellular HLBP identified in Monienza expansa [22,23]
and Hymenolepis diminuta [24,25] as well as extracellular HLBP
identified as secreted components of Taenia solium and Echinococcus
granulosus [26]. All these proteins have been found to be highly
abundant and immunogenic, and exists as high-molecular-mass
oligomers composed by a helix-rich subunits of about 7–11 kDa.
Related immunogenic proteins were also described in Taenia
crassiceps and Taenia hydatigena although their lipid-binding proper-
ties have not been analysed [26–29]. The ligand specificity of
intracellular HLBPs has been characterised in vitro [22–25]; they
bind saturated and unsaturated fatty acids (but not their CoA-ester
derivatives), retinoids, and some antihelminthic drugs, and the M.
expansa protein can also bind cholesterol. The in vitro lipid binding
properties of extracellular HLBPs has been partially examined by
binding assays using fluorescent lipid analogues and shown to bind
fatty acids only [26,30,31]. In the case of EgAgB, the delipidated
native molecule and the recombinant EgAgB8/1 and EgAgB8/2
apolipoproteins showed ability to bind a palmitic acid fluorescent
analogue with high affinity, but the possibility that these proteins
could bind lipids other than fatty acids was not evaluated [30].
Cestodes have a very restricted lipid metabolism. On the one
hand, lipids are not suitable substrates for energy metabolism
because they cannot be oxidised due to the limited aerobic
capacity of tissue-dwelling parasites (reviewed by [32] and [33]).
On the other hand, cestodes are unable to synthesise fatty acids,
phospholipids and cholesterol de novo. Yet, lipids are required for
biosynthetic purposes, and thus, parasite lipid-binding proteins
play a key role in cestode metabolism, as they are likely involved in
the uptake of lipids or their precursors from the host. In this
scenario, it is generally thought that EgAgB and its secreted
homolog could have an important role in the biology of cestodes,
controlling the acquisition and distribution of lipids to specific
tissues. Alternatively, it has been proposed that HLBPs could act
as messenger molecules by carrying signalling lipids which would
play a role in cell activation and/or differentiation processes
involved in parasite adaptation to the host immune system. In the
case of EgAgB, in vitro evidence suggests that this lipoprotein may
modulate host defenses by down-regulating neutrophils and
dendritic cell-mediated innate responses as well as T-cell
dependent mechanisms, which globally influence the intensity
and quality of the adaptive immune responses [34–37].
The present work was aimed at identifying the native lipid moiety
of EgAgB in order to complete our knowledge on the EgAgB
molecular composition; this information could simultaneously shed
lightintoEgAgBstructureandfunction.Ofparticularrelevancewas
to determine whether EgAgB binds in vivo lipid classes other than
fatty acids. For that purpose, we purified EgAgB to homogeneity,
using a protocol based on ion exchange chromatography coupled to
immunoaffinity with a monoclonal antibody (Mo EB7), and then
purified the EgAgB lipid moiety by extraction with organic solvents.
Characterisation of immunopurified EgAgB of bovine origin
showed that lipoprotein particles are constituted mostly by
EgAgB8/1 apolipoprotein and that the native lipid moiety of this
antigen comprises neutral and polar lipids that have not been
previously described as ligands of this HLBP family.
Materials and Methods
Reagents
Inorganic salts, 3,5-di-tert-butyl-4-hydroxytoluene (BHT), ethyl-
enediaminetetraacetic acid (EDTA) and authentic lipid standards
including cholesterol (CH), fatty acids (FA), triacylglycerols
(TAGs), phosphatidylethanolamine (PE), cardiolipin (CLP), phos-
phatidylinositol (PI), phosphatidylserine (PS) and phosphatidyl-
choline (PC) were acquired from Sigma Chemicals (USA).
Solvents (HPLC grade or better) and a-naphthol were purchased
from Merck (Germany) or Fisher Scientific (USA).
Parasite material
E. granulosus HCFs from cysts containing protoscoleces of bovine
origin were obtained by aspiration of the content of cysts present
Author Summary
The larva of the cestode parasite Echinococcus granulosus
affects a wide range of livestock mammals and humans,
causing cystic echinococcosis (hydatid disease), a zoonosis
with significant economic and public health impact. The
disease is characterised by the growth of a fluid-filled cyst
in the host’s viscera (mainly liver and lung). The most
relevant antigen for hydatid disease diagnosis is antigen B
(EgAgB), a highly abundant lipoprotein present in the cyst
fluid. There is overwhelming literature regarding EgAgB
antigenicity and molecular characterisation at the protein
and gene levels, but the knowledge of the lipids
physiologically bound to EgAgB protein subunits is very
scarce. Indeed, there is only one report showing that
delipidated EgAgB binds fatty acids in vitro. This work
describes the physiological lipids of EgAgB, an important
piece of information to complete our knowledge on
EgAgB molecular composition. In contrast to what was
thought, EgAgB consists of a variety of neutral and polar
lipid classes, associated to protein subunits, forming a
plasma lipoprotein-like particle of 229 kDa in size. Taken
into account that E. granulosus cannot synthesise fatty
acids and sterols, these data suggest that EgAgB plays a
role in the uptake and transportation of these essential
lipids across parasite structures.
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during the routine work of local abattoirs in Montevideo
(Uruguay). E. granulosus HCFs of human origin, collected from
surgically-removed hepatic hydatid cysts, were generously donated
by Dr A. Leites and Dr E. Torterolo (Hospital Militar,
Montevideo, Uruguay). All HCF samples were preserved by
addition of 5 mM EDTA and 20 mM BHT, and maintained at
220uC. For EgAgB purification, three batches of bovine HCF
(each one containing a pool of HCF from individual cysts) and two
samples of individual human HCF were used.
Purification of native EgAgB
Native EgAgB was purified from HCF following a previously
described protocol [20] with slight modifications. HCF was
centrifuged at 10000 g for 30 min at 4uC and the resulting
supernatant filtered consecutively through 5, 2, 0.8 and 0.45 mm
filter membranes (Millipore). The clarified HCF was firstly
fractioned by anion exchange chromatography on a Q-Sepharose
column (Pharmacia Biotech, Uppsala, Sweden) previously equil-
ibrated in 20 mM phosphate buffer, pH 7.2 containing 200 mM
NaCl, 5 mM EDTA and 20 mM BHT. After washing in
equilibration buffer, the retained material was eluted by changing
ionic strength to 400 mM NaCl in a single step. The eluted
fraction (enriched in EgAgB and almost free of host albumin and
immunoglobulins) was used to purify the antigen to homogeneity
by immunoaffinity chromatography based on the utilization of a
monoclonal antibody (MoAb) -named EB7- that specifically
recognises the native lipoprotein [20]. For this purpose, the Q-
Sepharose eluted fraction was diluted in 20 mM phosphate buffer,
pH 7.2 containing 5 mM EDTA and 20 mM BHT, to reach a
final concentration of 200 mM NaCl and then applied to the EB7-
Sepharose column. After washing, EgAgB was eluted with
100 mM glycine-HCl, pH 3, immediately neutralised with 2 M
Tris pH 9.6 and then equilibrated in 20 mM phosphate buffer,
pH 7.2 containing 5 mM EDTA and 20 mM BHT (PBS-EDTA-
BHT) using a PD-10 desalting column (Amershan, Biosciences).
The homogeneity of EB7-affinity purified EgAgB (immunopurified
EgAgB) was monitored by SDS-PAGE on 15% polyacrylamide
gels followed by silver stain. In addition, samples were analysed by
two-dimensional gel electrophoresis as described below.
Identification of EgAgB apolipoproteins by two
dimensional (2-D) gel electrophoresis and mass
spectrometry analysis
First dimension was performed with commercially available
IPG-strips (7 cm, linear 3–10, GE Healthcare). Immunopurified
EgAgB was prepared and concentrated by using the 2-D Clean-
Up kit (GE Healthcare) and dissolved in rehydration solution (7 M
urea, 2 M thiourea, 2% CHAPS, 0.5% IPG buffer 3–10 (GE
Healthcare), 0.002% bromophenol blue, DTT 17 mM). Samples
in rehydration solution were loaded onto IPG-strips by passive
rehydration during 12 h at room temperature. The isoelectric
focusing was done in an IPGphor Unit (Pharmacia Biotech)
employing the following voltage profile: constant phase of 300 V
for 30 min; linear increase to 1000 V in 30 min; linear increase to
5000 V in 80 min and a final constant phase of 5000 V to reach
total of 6.5 kVh. Prior running the second dimension, IPG-strips
were reduced for 15 min in equilibration buffer (6 M urea,
75 mM Tris–HCl pH 8.8, 29.3% glycerol, 2% SDS, 0.002%
bromophenol blue) supplemented with DTT (10 mg/ml) and
subsequently alkylated for 15 min in same equilibration buffer but
supplemented with iodoacetamide (25 mg/ml). The second-
dimensional separation (SDS-PAGE) was performed in 15%
polyacrilamyde gels using a SE 260 mini-vertical gel electropho-
resis unit (GE Healthcare). The molecular size markers used were
Amersham Low Molecular Weight Calibration Kit for SDS
Electrophoresis (GE Healthcare). The gels were silver stained
according to [38]. Images were digitalised using a UMAX Power-
Look 1120 scanner and LabScan 5.0 software (GE Healthcare).
Identification of protein spots was performed by mass
spectrometry (MS) using a 4800 MALDI TOF/TOF
TM (AB
Sciex). Briefly, peptide mass fingerprinting plus MS/MS ion
search of selected spots were carried out by in-gel trypsin
treatment (sequencing-grade, Promega) at 37uC, overnight.
Peptides were extracted from gels using 60% acetonitrile in
0.1% TFA, concentrated by vacuum drying. Peptides were further
concentrated and desalted using C18 reverse phase micro-columns
(OMIX Pippete tips, Varian). Peptide elution from micro-column
was performed directly into the mass spectrometer sample plate
with 2 ml of matrix solution (a-cyano-4-hydroxycinnamic acid in
60% aqueous acetonitrile containing 0.1% TFA). Mass spectra of
digestion mixtures were acquired in the MALDI-TOF/TOF mass
spectrometer using the reflector mode. Spectra were externally
calibrated using a mixture of peptide standards (Mix 1, AB Sciex).
For increased confidence of identification, selected peptides were
further fragmented by post-source decay (PSD) and collisional-
induced dissociation (CID). Proteins were identified by NCBI nr
database searching using the MASCOT program (Matrix Science
http://www.matrixscience.com/search_form_select.html) and using the
following search parameters: monoisotopic mass tolerance,
0.05 Da; fragment mass tolerance, 0.2 Da; carbamidomethyl
cysteine and methionine oxidation as variable modifications and
up to one missed tryptic cleavage allowed.
Lipid extraction and purification
Total lipids were extracted according to the methodology
described by [39], with slight modifications. Briefly, HCF
(previously concentrated 10-times using a Savant SpeedVac
System) or immunopurified EgAgB (1 mg protein in approxi-
mately 2 mL of PBS-EDTA-BHT) were mixed with 30 ml of a
CHCl3:CH3OH mixture (2:1) and vigorously shaken for 2 min-
utes. Next, the homogenate was filtrated and the extract washed
with NaCl solution to reach a final concentration of 0.73% and a
CHCl3:CH3OH:H2O ratio of 2:1:0.2 in volume. After vigorous
agitation for 1 minute, the separation of phases was achieved by
centrifugation at 2400 rpm for 20 min and the upper phase was
removed by aspiration and discarded. The lower phase containing
lipids was recovered and taken to dryness by rotary evaporation at
40uC under vacuum; last traces of solvent were removed by a
stream of N2 (g). Finally, the lipid fraction was dissolved in CHCl3
to a concentration of 10 mg/mL. As a control of lipid
contaminants in buffers and/or solvents, an equal volume of
PBS-EDTA-BHT was used in parallel for extraction. Purified lipid
extracts were stored at 220uC under N2(g) until analysis.
Quantitation of total protein and lipid content
The protein content of immunopurified EgAgB preparations
was determined using bicinchoninic acid in a microtitre plate assay
(BCA Protein Assay kit) with BSA as standard (Pierce, Rockford,
Ill.). Total lipids in EgAgB were determined gravimetrically by
weighting purified lipids immediately after extraction and solvent
removal under a stream of N2(g).
Qualitative and quantitative analysis of lipid extracts
Separation of lipid class components was performed by high-
performance thin layer chromatography (HPTLC) on Kieselgel 60
plates (Merck). HPTLC plates (10610 cm) were pre-washed by
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100uC for 30 min. Lipid samples (fractions obtained from HCF
and EgAgB and standards) were spotted manually using a micro-
syringe (Hamilton). Double development was initially carried out
as follows: plates were first half-developed using a mobile phase for
resolving polar lipids (PL), and after drying under a N2 (g) stream,
were developed to completion in a mobile phase for neutral lipids
(NL). Single development for resolving PL or NL was also
performed. The solvent systems used as mobile phase were: for PL
resolution- methyl acetate/isopropanol/chloroform/methanol/
0.25%KCl (25:25:25:10:9, v/v/v/v/v) and for NL resolution-
hexane/diethyl-ether/acetic acid (80:20:1, v/v/v). Lipid bands
were visualised by spraying the plates with 8% (m/v) CuSO4 in a
10% (v/v) H3PO4 aqueous solution, and heating at 140uC; the
identification of lipid classes was performed by comparison with
primary and secondary standards run on the same HPTLC plate.
The relative abundance of each lipid class respect to the total lipid
content could not be estimated because not all lipids were resolved
adequately in a single HPTLC using double development. We
estimated the percentage of individual lipid classes in the total of
NL or PL instead. 1-nonadecanol was used as internal standard for
normalization. HPTLC plates were scanned and the intensity of
the bands was determined using the ImageJ software (http://rsb.
info.nih.gov/ij/). In addition, specific staining for sterol esters/
sterols and glycolipids were carried out using FeCl3.6H2O and a-
naphthol, respectively [40]. For the latter analysis a lipid fraction
from murine macrophage-like J774.A1 cells was prepared to use as
a control. Briefly, J774.A1 cells (generously donated by Dr. M.
Noel Alvarez, Departamento de Bioquı ´mica, Facultad de
Medicina, UdelaR) were washed with PBS, lysed using a
hypotonic solution (0.25 mM phosphate 3.75 mM NaCl) and
centrifuged (150006g,4 uC for 30 min) to obtain a cell membrane
enriched fraction. Lipids were then extracted following the Folch
method as described above.
Fatty acid analysis by gas-liquid chromatography (GC)
The fatty acid composition of EgAgB and HCF lipid fractions
was analysed by gas-liquid chromatography of their methyl esters
derivatives (FAMEs); for these studies material of both human and
bovine origin were used. Lipid fractions were subjected to acid
methanolysis with 1% H2SO4 in methanol at 50uC for 16 h. The
purified FAMEs were dissolved in hexane and then subjected to
GLC analysis on a Hewlett-Packard 5890 equipped with a
Carbowax 20 capillary column and flame ionisation detector
(FID). The oven temperature was initially set at 180uC for 10 min,
and then increased at 2.5uC/min to 212uC, level at which was
held for 10 min. The individual FAMEs peaks were identified by
comparison of their retention times with those of authentic
FAMEs standards.
Determination of the molecular weight of native
immunopurified-EgAgB by Size-Exclusion
Chromatography with on-line Multiangle Light-
Scattering (SEC-MALLS)
Light scattering analysis was carried out using a Superset 200
HR 10/30 SEC column (Amersham Biosciences, Piscataway, NJ),
connected to an HPLC system (Schimatzu) at room temperature.
Immunopurified EgAgB (200 mL of a 0.7 mg/mL solution in PBS)
was applied onto the column previously equilibrated in PBS, and
elution was monitored with on-line detection using the following
detectors: multiangle laser light scattering (miniDAWN system,
Wyatt Technology Corporation, Santa Barbara, CA), ultraviolet
UV (SPD-20A, Shimadzu) and differential refractive index (RID-
10A, Shimadzu). In addition, plasma-derived high density
lipoprotein (HDL) was analysed in the same conditions for
comparison. For HDL preparation, human plasma was obtained
from a healthy donor and HDL purification was carried out
following conventional ultracentrifugation methods [41]. A written
consent was obtained from the donor according to the Ethic
Committee of the Faculty of Chemistry (UdelaR) and the
Executive Decree Nu 379/008. Light scattering data were
collected and processed with ASTRA software (v4.73.04, Wyatt
Technology) using the Debye fit method with a dn/dc ratio set to
0.186 mL/g [42].
Results
EgAgB8/1 is the major apolipoprotein component of
EgAgB immunopurified from bovine HCF
Most studies were performed with EgAgB of bovine origin since
the availability of parasite material of human origin was very
limited. EgAgB was purified to homogeneity from bovine HCF
using a previously described procedure based on selective
adsorption of this antigen on Q-Sepharose followed by immu-
noaffinity chromatography using immobilised MoAb EB7 [20].
This purification methodology was found to be suitable for the
main objectives of this work, as it has been shown that affinity
immunoadsorption permits isolation of lipoproteins under mini-
mally perturbing conditions [43]. We characterised the apolipo-
protein component of bovine EgAgB using 2-D gel electrophoresis
and found that it contained two major spots electrofocused at
pH 8.8 and 9.6 (Figure 1A, arrows). These two spots were
identified as EgAgB8/1 by mass spectrometry analysis. Identifica-
tion was mainly due to the analysis of the data arising from two
main peptide signals with m/z of 1275.68 and 1399.69 that
matched with the ELEEVFQLLR and YFFERDPLGQK se-
quences, respectively. These peptides lie in conserved regions of
the amino acid sequence of EgAgB8/1. Therefore, we cannot
discriminate which ones of the already described EgAgB8/1
isoforms is present in the samples. These isoforms include
molecules having different theoretical isoelectric point
(Figure 1B). In the case of the most basic spot, focused at
pH 9.6 (Figure 1A, arrow), an additional peptide matching the
MFGEVK sequence (Figure 1B, dashed line box) was observed.
This sequence is present in at least four EgAgB8/1 isoforms.
Interestingly, only one of them has a theoretical pI of 9.52,
matching the observed value (Figure 1B, solid line box). A minor
spot electrofocused at pH 7.9 was also detected (Figure 1A, head
arrow), and peptide mass spectrometry of this spot indicated that it
also corresponded to EgAgB8/1. When higher amounts of antigen
(3-fold) were analysed, EgAgB8/4 was detected; identification was
mainly based on the presence of a signal with m/z=1152 that
matched with the LGEIRDFFR sequence, which is only present in
EgAgB8/4 isoform (data not shown).
The lipid component of immunopurified EgAgB is highly
heterogeneous, containing a variety of neutral and polar
lipid classes
Previous work suggested that EgAgB8 apolipoproteins are
capable of binding fatty acids [30]. However, the fact that HCF,
the physiological milieu to which EgAgB is secreted, contains a
wide range of neutral and polar lipids [44,45], opens up the
possibility that the putative physiological ligands of EgAgB8
apolipoproteins include a more diverse set of lipids. For
identification of these ligands, we firstly purified the lipid fractions
of both, EgAgB and the HCF from which this antigen was
immunopurified, using parasite material of bovine origin via the
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analysis of lipoproteins and has the advantage of solubilising all
major lipid classes using a single solvent mixture, even though it
does not allow the protein to be recovered because this fraction
irreversibly precipitates during the procedure. From the dry mass
of total lipids extracted and the protein concentration of the
starting sample we estimated the lipid:protein ratio (w:w), finding
that it was plainly higher for immunopurified EgAgB (between
0.6:1 and 1.1:1, n=3 independent batches) than HCF (between
0.17:1 and 0.19:1, n=3 independent batches). This implies that
the lipid fraction of EgAgB represented approximately 40–50% of
its total mass.
As an initial approach for examining the complexity of lipid
classes, HCF and EgAgB lipids were analysed by HPTLC using
double development. Under these conditions the majority of
neutral and polar lipids are clearly separated, although the
resolution of some lipid classes may not be optimal. By analysing in
parallel a mixture of authentic lipid standards, we observed that
the natively-bound lipid component of immunopurified EgAgB is
highly heterogeneous, comprising several lipid classes, all of which
are also found in the HCF. Indeed, the lipid fractions of both
EgAgB and HCF showed to contain a wide variety of lipid classes
from very hydrophobic ones (compatible with sterol esters and
TAGs) to charged ones (phospholipids) (Figure 2A); this pattern
was obtained for EgAgB and HCF samples derived from three
independent batches (data not shown). Thus, these results
indicated that the lipid fraction of EgAgB particles carrying
EgAgB8/1 apolipoproteins consists not solely of fatty acids, but
also of a variety of polar and neutral lipids present in HCF. For
comparative purposes, we analysed the lipid fraction of EgAgB
immunopurified from HCF of human origin (two independent
batches), finding similar results in terms of lipid:protein ratio as
well as lipid class composition (data not shown).
In order to improve the identification of the lipid classes of
EgAgB, the EgAgB lipid fraction was analysed by HPTLC using
conditions for resolving separately neutral and polar lipids; in this
analysis, 1-nonadecanol was added to all samples as an internal
standard (IS) for normalization. This analysis was carried out only
for HCF and EgAgB of bovine origin. As shown in Figures 2B and
2C, the lipid composition of EgAgB and HCF was very similar in
terms of the variety of lipid classes. Among neutral lipids, three
classes were assigned considering their mobility in comparison
with standards: TAGs, free sterols and free fatty acids. In addition,
three components having higher mobility than TAGs were
observed in both EgAgB and HCF lipid fractions. Among these,
there was a component that migrated slightly faster than FAMEs
but slower than cholesteryl laureate, being compatible with
dialkyl-monoacylglycerols and/or alkenyl-diacylaglycerols [40].
The other two components were not completely resolved and
migrated as a wide smear in the assay conditions. The least mobile
Figure 1. EgAgB8/1 is the major apolipoprotein component of EgAgB immunopurified from bovine HCF. A) Immunopurified EgAgB of
bovine origin was analysed by 2-D gel electrophoresis using a 3–10 lineal gradient of pH in the first dimension, 15% acrylamide gel for SDS-PAGE and
silver staining for development. Two main spots focused at pH of 9.6 and 8.8 are observed (arrows); a minor component focused at pH 7.9 is also
indicated (head arrow). Identification of spots observed in A) was carried out by mass spectrometry as detailed in 2.4. Panel B) shows the amino acid
sequences corresponding to various isoforms described for EgAgB8/1 in which are indicated: the main peptides found in all spots (in bold) and a
peptide detected only from the analysis of the more basic spot (within a box). The theoretical isoelectric point (pI) and molecular weight (MW) of
each EgAgB8/1 isoform are shown (determined using Compute pI/MW Expasy tool at http://web.expasy.org/compute_pi/).
doi:10.1371/journal.pntd.0001642.g001
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according to the mobility of cholesteryl laurate. This was
confirmed by using a sterol ester-specific staining method based
on the formation of a purple complex with FeCl3 at acid pH
(Figure 3A). The most mobile component was also observed in the
control, indicating that it corresponded to a very hydrophobic
contaminant derived from the extraction procedure. A second
contaminant having a very low mobility in the assayed conditions
was also detected in the control.
With respect to polar lipids, the analysis of EgAgB and HCF in
parallel with phospholipid standards showed that phosphatidyl-
choline was the main phospholipid present in both samples.
Phosphatidylethanolamine, phosphatidylinositol and phosphati-
dylserine were also detected in smaller amounts as well as traces of
cardiolipin. Furthermore, minor components with higher mobility
than phospholipids but lower than neutral lipids compatible with
glycolipids were observed. The presence of glycolipids was
confirmed by staining with a-naphthol, a dye that specifically
reacts with sugar groups (Figure 3B).
The relative abundance of the major lipid classes found in
immunopurified EgAgB and HCF within total neutral or polar
lipids was estimated as shown in Figure 4. This estimation was
carried out by analysing the intensity of HPTLC bands by
densitometry, for which errors due to unequal sample application
or irregular staining across the plate were normalised using the
internal standard. TAGs and phosphatidylcholine corresponded to
the most abundant neutral and polar lipids of EgAgB, reaching
around 30% and 60%, respectively; similar percentages of these
lipids were found in HCF. Moreover, the relative abundance of
any lipid class within neutral and polar lipids was almost identical
for EgAgB and HCF, suggesting a non-selective binding of lipids
by EgAgB8/1 apolipoproteins. It is worth to mention that the
relative abundance values are likely affected by two factors
inherent to the method: i) the fact that the intensity of staining
does not follow the same proportionality with the lipid mass for the
different lipid classes, and ii) the spreading of the band affects
densitometry, which means that how each lipid is resolved/focused
during the chromatography could influence its quantitation.
The main fatty acids present in immunopurified EgAgB
are 16:0, 18:0 and 18:1(n-9)
We next analysed the fatty acid composition of total lipids
extracted from human and bovine EgAgB and HCF (Figure 5).
Globally, the results revealed that the fatty acid profiles of EgAgB
obtained from both sources were very similar. The predominant
fatty acids were 16:0, 18:0 and 18:1(n-9), while 18:2(n-6) and
20:4(n-6) were present in a much lower proportion. Other fatty
acids were present in minor quantities, representing less than 5%
each. Furthermore, the content of fatty acids in EgAgB closely
resembles that of the HCF used for its purification, suggesting that
Figure 2. The lipid fractions of EgAgB and HCF are similar and include a variety of neutral and polar lipids. The lipid fractions of bovine
EgAgB and its corresponding HCF were analysed by HPTLC using double development (A) or in conditions for resolving separately neutral (B) and
polar (C) lipid classes. Standards (between 2 and 8 mg) and samples (around 5 and 10 mg) were applied onto HPTLC plates; 1-nonadecanol was added
as internal standard (IS) for normalization purposes. Lipid bands were visualised using CuSO4/H3PO4 and identified by comparison with the standards.
The profile is representative of three EgAgB and HCF batches, which were independently analysed. The wedges indicate increasing amount of
loading samples. NLStd: neutral lipid standard; CH: cholesterol; FA: free fatty acid; TAG: triacylglycerols; FAMEs: fatty acid methyl esters; CL: cholesteryl
laurate; PLStd: polar lipid standard; PC: phosphatidylcholine; PS: phosphatidylserine; PI: phosphatidylinositol; CLP: cardiolipin and PE:
phsophatidylethanolamine.
doi:10.1371/journal.pntd.0001642.g002
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abundant fatty acids of HCF in a non-selective manner.
Nevertheless, EgAgB8/1 apolipoproteins showed some degree of
selectivity in fatty acid binding properties since the relative
abundance of 13:0, 16:0, 18:0 and 18:1(n-9) were similar in bovine
HCF, but not in bovine EgAgB, which contained lower percentage
of 13:0 and higher percentage of 18:1(n-9) than bovine HCF. The
comparison of the relative abundance of fatty acids in bovine vs.
human HCF strongly suggests that the fatty acids are taken from
the host, since 13:0, a more abundant fatty acid in ruminants, was
found in higher levels in bovine than human HCF (14 vs. 3% of
total fatty acids).
Native EgAgB comprises a heterogeneous population of
particles having a size distribution similar to HDL
Bovine EgAgB was analysed by SEC to study its physical state in
aqueous solution. EgAgB eluted as a main peak centered at
12.5 mL, from which an apparent MW of 160 kDa was estimated
Figure 4. Relative abundance of the main lipid classes present in EgAgB and HCF. EgAgB and HCF of bovine origin were separately
analysed by HPTLC in conditions to resolve neutral or polar lipids. The percentage of each lipid class in the total of neutral or polar lipids was
estimated by densitometry. Results are expressed as mean values obtained for three different batches of EgAgB and HCF, which were analysed in
duplicates. The question mark corresponds to a lipid class whose identity is based solely on its HPTLC mobility. CH: cholesterol; TAG: triacylglycerols;
CL: cholesteryl laurate; PC: phosphatidylcholine; PS: phosphatidylserine; PI: phosphatidylinositol; CLP: cardiolipin; PE: phosphatidylethanolamine.
doi:10.1371/journal.pntd.0001642.g004
Figure 3. Immunopurified EgAgB lipid moiety include sterols, sterol esters and glycolipids. (A) The lipid fractions (around 10 mg) of
bovine EgAgB and its corresponding HCF were applied on HPTLC plates and chromatographed using a solvent system for resolving neutral lipids.
Development was performed using an acidic ferric chloride solution for specific staining of sterols/sterol esters as violet bands. NLStd, containing
cholesterol, cholesteryl laurate, triacylglycerides and free fatty acids, was analysed in parallel as a control. (B) The lipid fraction (around 2 and4mg) of
bovine EgAgB was applied on HPTLC plates and chromatographed using a solvent system for resolving polar lipids. Development was carried out
using both, a general (CuSO4/H3PO4) and a glycolipid specific stain employing a-naphthol, which yields glycolipids as purple bands. As a control a cell
membrane extract (Cell Ext) was analysed in parallel. The wedges indicate increasing amount of loading samples. CH: cholesterol; TAG:
triacylglycerols; CL: cholesteryl laurate; PC: phosphatidylcholine; PS: phosphatidylserine; PI: phosphatidylinositol; CLP: cardiolipin; PE:
phosphatidylethanolamine.
doi:10.1371/journal.pntd.0001642.g003
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with previous results [1,2]. In order to determine the absolute MW
independently of hydrodynamic assumptions, we also analysed the
MW of bovine EgAgB by SEC-MALLS. The molecular mass
curve obtained by SEC-MALLS displayed two phases (Figure 6):
an initial sharp decrease of the size at the beginning of elution
(started at molecular-mass species of ,400 kDa), rapidly followed
by a plateau at a calculated mass of ,229 kDa, which included the
maximum and extended to the end of the peak. This behaviour
suggests that EgAgB exists in solution as a heterogeneous
population of lipoprotein particles, with most species showing an
average molecular mass of 22967 kDa. This heterogeneity could
be, at least partially, associated to the capacity of EgAgB
apolipoproteins to form particles accommodating variable
Figure 5. Relative abundance of total fatty acids of immunopurified EgAgB and HCF lipid fractions. The methyl ester derivatives of total
(free and esterified) fatty acids (FAMEs) were prepared from EgAgB and HCF lipid fractions and then analysed by GLC. The graphic shows the relative
abundance of identified components calculated as the percentage of each fatty acid referred to the total content. In the cases where the resolution of
two components was partial, their abundances were taken together (i.e. 16:1(n-7/9) refers to the content of 16:1(n-7) y 16:1(n-9)). The values
correspond to the mean 6 std of two batches of EgAgB and HCF of bovine and human origin.
doi:10.1371/journal.pntd.0001642.g005
Figure 6. Solution behaviour of native EgAgB characterised by SEC-MALLS. Representative SEC-MALLS analysis of native EgAgB after
immunopurification from bovine HCF. The solid curve represents the UV absorbance profile at 280 nm, overlaid with the scatter plot, which
corresponds to the mass estimated from light scattering profile and concentration measurement, versus the elution time. The calculated molecular
masses are given in the text. The inset shows the MALLS analysis of human HDL (top), and that of bovine EgAgB (bottom) for comparison.
doi:10.1371/journal.pntd.0001642.g006
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have some tendency to self-associate, leading to the formation of
(less abundant) higher-order oligomers. On the other hand, the
lipid/protein mass ratio, lipid composition and size of EgAgB
suggested that, globally, it exhibits compositional and dimensional
characteristics resembling those of plasma HDL. For comparison,
human HDL was then analysed by SEC-MALLS under the same
conditions. HDL showed a similar SEC-chromatographic profile
to EgAgB, exhibiting molecular mass species from 150 to
400 kDa, with a mean MW of 20964 kDa (Figure 6, inset).
Discussion
This work aimed at characterising the native lipid moiety of
EgAgB. As we have already mentioned, studies were mainly
performed with EgAgB of bovine origin, yielding data that
improve our knowledge on EgAgB lipoprotein composition. In
addition, the characterisation of EgAgB protein:lipid ratio and
EgAgB lipid composition (major lipid classes and total fatty acids)
was carried out with limited amounts of human EgAgB, obtaining
similar results that confirm our findings.
EgAgB was purified from HCF using a previously described
method based on anion exchange followed by immunoaffinity on
MoAb EB7-Sepharose [20]. For a complete description of the
lipoprotein composition we firstly characterised the apoliprotein
component of immunopurified EgAgB of bovine origin. In
addition, the identification of the apolipoprotein subunits forming
EgAgB is relevant because the lipid-binding properties of EgAgB8
isoforms may differ. Native as well as recombinant EgAgB8/1 and
EgAgB8/2 did not show differences in their capacity to bind fatty
acid analogues in vitro [30]. Nevertheless, the physiologic lipid
ligands of EgAgB8 isoforms could depend not only on the lipid-
binding properties of individual isoforms, but also on the cell/
tissue compartment where they are synthesised, assembled and/or
transported (e.g. germinal layer vs. protoscolex). We found that
EgAgB8/1 was the major apolipoprotein component of immuno-
purified EgAgB (Figure 1), while EgAgB8/4 was detected in much
smaller amounts. In the original article describing this purification
method, peptides matching sequences of EgAgB8/1, EgAgB8/2
and EgAgB8/4 were found, although those corresponding to
EgAgB8/4 (SDPLGQK and LGEIR) were not initially assigned to
this molecule, because its sequence was unknown. The purification
of lipoproteins carrying EgAgB8/1 agrees with the fact that
EgAgB8/1 is expected to be present in HCF of bovine origin [46]
and MoAb EB7 strongly reacts with this isoform [20]. In contrast,
MoAb EB7 does not bind to EgAgB8/2 [20] and it is unlikely that
it binds to EgAgB8/4 since this isoform has much higher similarity
to EgAgB8/2 than to EgAgB8/1 [18]. Therefore, purification by
this method of particles carrying EgAgB8/2 and/or EgAgb8/4
apolipoproteins may result from lipoprotein particles carrying
EgAgB8/1 along with EgAgB8/4 and/or EgAgB8/2, and/or
associative interactions between lipoprotein particles carrying
different EgAgB8 isoforms. In this regard, it is worthy to note
that association of EgAgB particles could occur according to the
EgAgB analysis by SEC-MALLS (Figure 6) and previous
observations made by studying EgAgB sedimentation equilibrium
[2]. The fact that we did not detect EgAgB8/2 in immunopurified
EgAgB of bovine origin may be due to the sensitivity of the
technique or to variations in the composition of distinct HCF
pools. Indeed, the presence of EgAgB8/2 was detected in bovine
HCF by Chemale et al. [30] but not by Aziz et al. [46] and it seems
to be more variable than that of EgAgB8/1 and EgAgB8/4 among
cysts of different origin/fertility [46]. Furthermore, EgAgB8/2
would not be one of the most abundant EgAgB isoforms in the
HCF according to the expression levels of EgAgB family in E.
granulosus metacestode [18]. Therefore, the characterisation of the
apolipoprotein composition of EgAgB highlights that HCF-
derived EgAgB preparations may differ depending on parasite
material and these differences may be relevant when analysing
EgAgB structural and/or functional properties. In any case, since
EgAgB8/1 is highly expressed in the E. granulosus metacestode
[18,19], the EgAgB8/1-enriched lipoprotein that we used for lipid
characterisation likely represents one of the most abundant
lipoproteins of the EgAgB family present in HCF.
Analysis of the lipid composition of immunopurified EgAgB of
both bovine and human origin, revealed a high diversity in terms of
lipid classes ranging from highly hydrophobic lipids (mainly TAG,
but also sterol esters) to a variety of phospholipids (mainly
phosphatidylcholine). These findings indicate that EgAgB is a more
complex lipoprotein than previously suggested from lipid-binding
studies in vitro, in which fatty acids were described as the main lipid
ligands of EgAgB8/1 and EgAgB8/2 [30]. Also, these results set
EgAgB apart from the fatty acid binding protein family, whose
members bind mainly fatty acids [47]. On the other hand, the fact
that the lipid moiety of immunopurified EgAgB represented
between 40 and 50% of the total mass reveals that EgAgB require
to adopt a very well organised structure to accommodate a high
proportion of lipid molecules in a single particle, suggesting
similarities with animal lipoproteins found in both invertebrate
hemolymph and vertebrate plasma [48]. The structural organiza-
tion of these animal lipoproteins is well established; the most
hydrophobic lipids (triacylglycerols, cholesteryl esters and other
lipid-soluble components) are sequestrated in a central core,
surrounded by an external hydrophilic shell that contains the
apolipoproteins and amphipathic lipids (mostly phospholipids and
unesterified cholesterol) (review by [49]). A structure like this could
explain theheterogeneityofmolecular mass speciesobserved during
analysis of immunopurified EgAgB by SEC-MALLS. Among
vertebrate plasma lipoproteins, EgAgB would be more similar to
the smallest HDL particles, referred to as HDL3 [48,50], which
exhibits a lipid:protein mass ratio (w:w) between 0.67:1 and 1.2:1
(0,6:1–1.1:1 for EgAgB) and an average molecular mass of 200 kDa
(229 kDa for EgAgB); the comparative analysis of HDL and EgAgB
by SEC-MALLS supports this hypothesis (Figure 6, inset). However,
the content of TAG in EgAgB is much higher than in HDL3, which
likely reflects differences in the lipid transport function of these
lipoproteins. In addition, in the context of this structural organisa-
tion share by all plasma lipoproteins, and taken into account its size
and chemical composition, each EgAgB particle would contain
between 11 and 15 EgAgB8 apolipoprotein molecules inserted into
the outer phospholipid monolayer. This new scenario is relevant
when considering the biological effects of EgAgB through parasite’s
as well as host’s receptors. The exposure of more than a dozen of
apolipoproteins on the surface of the lipoprotein particle would
facilitate the establishment of multiple interactions with receptors,
increasing the avidity of the interaction and the signals derived from
it. The formation of multiple EgAgB-B cell interactions likely
contributes to the immunogenicity of this lipoprotein. On the other
hand, it cannot be ruled out that lipids could participate, at least
partially, in some of the EgAgB biological activities (for example
those anti-inflammatory described in vitro). Surface charge and/or
hydrophobic distribution resulting from a lipoprotein ensemble (as
opposed to lipid or protein fractions alone) may alter the type of
receptors involved, affecting its physiological effects.
The identification of the native lipid ligands of EgAgB provides
relevant information for studying the function of this HLBP family
member. Evidence for HLBP-mediated fatty acid binding and
transportation across parasite membrane has been obtained in
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are likely involved in solubilising and stabilising a variety of
insoluble lipids in a lipoprotein particle, and that this may have an
important role to deliver lipids from the tissues/sites where are
synthesised/sequestered, to those that utilise or storage them. The
fact that the lipids present in EgAgB are not only fatty acids, but
also other essential building blocks such as sterols, highlights that
EgAgB could serve a role for the E. granulosus metabolic demand of
lipids. In this context is important to highlight that no enzymes for
either fatty acid anabolism or squalene synthesis (the precursor of
the whole family of animal sterols) have been found in the E.
granulosus transcriptome (data base http://www.compsysbio.org/
partigene/) or the Echinococcus multilocularis genome (unpublished
observations, http://www.genedb.org/Homepage/Emultilocularis).
In addition, metabolic studies have demonstrated that sterol
synthesis in E. granulosus seems to stop at the level of farnesyl or
nerolidol pyrophosphate and that the content of cholesterol in HCF
derives from the cholesterol pool of the host [51,52]. Thus,
E. granulosus needs to take these lipids from its host. Whether EgAgB
apolipoproteins are directly involved in the uptake of fatty acids and
sterols from host tissues remains to be elucidated, but most likely
they contribute to transport these lipids within metacestode tissues.
Delivery of sterols to metacestode target cells may be crucial for
biosynthetic purposes (i.e. cholesterol for biological membranes),
but also for triggering signaling pathways associated with parasite
development and growth. In fact, signaling pathways involving
sterol-responsive nuclear receptors are conserved from simple
invertebrates to mammals and regulate metabolism and develop-
ment [53].Forsignalling actions host sterols maybe modified bythe
parasite; indeed, a couple of putative steroid modifying enzymes
have been found in the E. granulosus trasncriptome (our unpublished
observations). Interestingly, about twenty nuclear receptors have
been recently identified in E. multilocularis and E. granulosus and one
of them displayed structural similarities to the DAF-12 subfamily,
which binds cholesterol modified compounds and regulates
cholesterol homeostasis and longevity in metazoans [54]. In
addition, TAG are also a major component of EgAgB. TAG are
not synthesised de novo by E. granulosus, but may be synthesised from
building blocks obtained from the host as it occurs in other cestodes
[33]. Metabolic studies have not been performed in Echinococcus, but
evidence of TAG synthesis via a-glycerophosphate–phosphatidic
acid-diglyceride pathway exists for the cestode Hymenolepis diminuta
[55]. TAG are the major reserve of energy in animals, but no
evidence on the operation of fatty acid oxidation pathways has been
obtained in flatworms [33] including Echinococcus (our unpublished
observations from the E. granulosus transcriptome). This scenario
suggests that TAG mainly provide a source of fatty acids and
glycerol for synthetic purposes via an enzymatic hydrolysis.
Consistent with this view is the identification of two ESTs clusters
(EGC01304 and EGC 03444) that encode putative lipases in the E.
granulosus transcriptome data base. With respect to the high content
of phospholipids in EgAgB (mainly phosphatidylcholine), these
molecules likely play a structural role in the lipoprotein by exposing
a polar outer surface required for lipoprotein solubilization in the
aqueous milieu. Phospholipids are not synthesised de novo by
flatworms, but they can be synthesised from building blocks
obtained from the host (fatty acids and the head group) [33].
The uptake and delivery of lipids by lipoproteins require the
existence of lipoprotein receptors in target cells. The existence of
parasite EgAgB receptors as well as the use of host receptors by
EgAgB would be needed for EgAgB-mediated lipid traffic. In this
sense it is worth to mention that in E. multilocularis and E. granulosus
genomes, antigen B gene cluster is flanked by EmLDLR or EgLDLR
genes, which encode proteins that display significant sequence
similarities to low density lipoprotein (LDL) receptors from other
species, and contain one single class A LDL receptor domain [19].
The N-terminal end of the LDL receptor contains seven successive
class A domains (a cysteine-rich repeat of about 40 amino acids),
which are involved in the binding of LDL as well as very low
density lipoprotein (VLDL) [56]. Furthermore, domains with
homology to class A LDL receptor occur in related lipoprotein
receptors such as VLDL receptor as well as LDL receptor-related
protein/alpha 2-macroglobulin receptor [57,58].
Overall, a new picture for EgAgB structure and function has
emerged from this work. EgAgB is a complex 229 kDa lipoprotein
capable of transporting a variety of lipid classes including essential
lipids that are not synthesised by the parasite, such as fatty acids
and sterols. EgAgB uptake and delivery of these lipids may not
only contribute to biosynthetic purposes, but also to signalling
events associated with parasite metabolism and development.
Whether the hydrophobic ligand binding properties of EgAgB,
reflected by its lipid class composition, are an intrinsic feature of
cestode HLBP family remains to be determined.
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